Home » Living with Neuroendocrine Cancer » Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

Recent Posts


I wanted to do a full-blown post about Immunotherapy but there is so much stuff out there!  However, I also wanted to break it down and perhaps see if I can pick up the what, when, why, where and how in regards to Neuroendocrine Cancer.  It’s really difficult, not least because the picture is not clear and there is no general roadmap printed, let alone one for Neuroendocrine disease.  Immunotherapy for NETs was discussed at ENETS 2017 in Barcelona.  The presentation that sticks out was one given by Dr Matthew Kulke, a well-known NET Specialist in Dana Ferber Boston. My reaction to the presentation was one of ‘expectation management’ and caution i.e. it’s too soon to know if we will get any success and when we will get it. He also hinted it is more likely that any success will first be seen in poorly differentiated high-grade (grade 3b) Neuroendocrine Carcinoma (NEC).  Dr Jonathan Strosberg also said similar in a post here.  In fact, from below you will see that grade 3 is where the bulk of trial activity is (…..but read on).

So, what’s all the hype about Pembrolizumab (Keytruda)?

The title of this post includes ‘Pembrolizumab’ better and more famously known as ‘Keytruda‘.   Before I talk about this trial called PLANET, it’s very useful to take a quick look at the history of Keytruda which was only really made famous after former US President Jimmy Carter was treated with it for metastatic melanoma.  There was a lot of media hype surrounding what made his treatment successful as he was also given radiation for his brain tumours and his large liver tumour was removed by surgery.  However, putting the hype and conjecture to one side, Keytruda’s CV is pretty impressive:

Pembrolizumab (Keytruda) is currently approved to treat:

  • Hodgkin lymphoma in adults and children. It is used in patients whose disease is refractory (does not respond to treatment) or has relapsed after at least three other types of treatment.
  • Melanoma that cannot be removed by surgery or that has metastasized (spread to other parts of the body).
  • Non-small cell lung cancer that has metastasized. It is used:
    • With pemetrexed and carboplatin as first-line treatment in patients with nonsquamous disease.
    • As first-line treatment in patients whose cancer has the PD-L1 protein and does not have a mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene.
    • In patients whose cancer has the PD-L1 protein and got worse during or after treatment with platinum chemotherapy. Patients whose cancer has EGFR or ALK gene mutations should receive Pembrolizumab only if their disease got worse after treatment with an FDA-approved therapy for these mutations.
  • Squamous cell carcinoma of the head and neck that has metastasized or recurred (come back) in patients whose disease got worse during or after treatment with platinum chemotherapy.
  • Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in patients who cannot be treated with cisplatin or whose disease got worse during or after platinum chemotherapy.
  • Microsatellite instability-high (MSI-H) cancer that is metastatic and cannot be removed by surgery. It is used in adults and children for:

    MSI-H cancer has certain genetic mutations and may not respond to some types of treatment.

The most recent approval in May 2017 MSI-H disease is a very interesting development as it’s the US FDA’s very first approval on a tissue/site agnostic basis.  You can read about this approval here.  Cancers of the breast, prostate, thyroid, bladder, colon, rectum and endometrium are just some of the cancers that have been found to have these biomarkers and would be new possible targets for Keytruda. There’s a great article which explains this approval in an easy way – click here to read.

Other approvals are anticipated.

So what about NETs and NEC? 

I found the following trials for high-grade NEC:

Please also see the wonderful work done by NET Research Foundation who are using their funds to explore the use of Immunotherapy in NETs – check out their update by clicking here.

So what about just plain old NETs? 

This trial is quite exciting as it involves the use of Pembrolizumab in combination with Lanreotide for patients with non-resectable, recurrent, or metastatic well or moderately (sic) differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). i.e. most of us.  It is not yet recruiting BUT the fact that a trial infrastructure is being put into place is very exciting. You can read about this trial by clicking here.  (Please note the incorrect reference to ‘moderately differentiated’ – this is no longer used in the grading classification for Neuroendocrine Neoplasms).

What is Immunotherapy?

For those still wondering what cancer immunotherapy actually is, this is the most basic description I could find!

 

Immunotherapy – Hype or Hope?

You may also enjoy this CNN article about the hype and hope aspect, it was given considerable sharing at ASCO17 – read the article by clicking here 

If you’re on an Immunotherapy trial not listed here, please let me now so I can update the post.  Thanks in advance.

 

 

 

Thanks for reading

Ronny

Hey, I’m also active on Facebook.  Like my page for even more news.

Disclaimer

My Diagnosis and Treatment History

Most Popular Posts

Sign up for my twitter newsletter

Check out my Podcast (click and press play)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

community_titled_transparent_2013-10-22

 


2 Comments

  1. Donna spas says:

    So at this point should we be asking for some sort of test to find out if we have this Gene…
    What specifically should we ask for?


    https://polldaddy.com/js/rating/rating.js

    Liked by 1 person

    • Ronny Allan says:

      I have no idea Donna, this is somethimg for your specialist. I’m also hoping the NET RF immunotherapy team would have seen this news and incorporated it into their own NET research. Personally I doubt if anyone has looked at Neuroendocrine yet.

      Like

Thanks for the comment, make sure you have ticked the box to receive notifications of responses

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Blog Stats

  • 311,580 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 9,178 other followers

Recent Posts

%d bloggers like this: